Differential Terminal Fucosylation of N-Linked Glycans Versus Protein O-Fucosylation in Leukocyte Adhesion Deficiency Type II (CDG IIc)*
- Laura Sturla‡,
- Raajit Rampal§,
- Robert S. Haltiwanger§,
- Floriana Fruscione¶,
- Amos Etzioni∥ and
- Michela Tonetti¶**
- ‡Giannina Gaslini Institute, 16147 Genova, Italy, the §Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, State University of New York at Stony Brook, New York 11794-5215, ¶Department of Experimental Medicine, University of Genova and Center of Excellence for Biomedical Research, 16132 Genova, Italy, and the ∥Department of Pediatrics, Meyer Children Hospital, Rambam Medical Center and B. Rappaport School of Medicine, Technion, 31096 Haifa, Israel
- ** Supported by CNR Target Project Biotechnology, by CNR Agenzia 2000, and by CNR/MURST Project (Legge 95/95). To whom correspondence should be addressed: Dept. of Experimental Medicine, Viale Benedetto XV, 1 16132 Genova, Italy. Tel.: 39-010-3538151; Fax: 39-010-354415; E-mail: tonetti{at}unige.it.
Abstract
LAD II/CDG IIc is a rare autosomal recessive disease characterized by a decreased expression of fucosylated antigens on cell surfaces that results in leukocyte adhesion deficiency and severe neurological and developmental abnormalities. Its molecular basis has been identified as a defect in the transporter of GDP-l-fucose into the Golgi lumen, which reduces the availability of the substrate for fucosyltransferases. During metabolic radiolabeling experiments using [3H]fucose, LAD II fibroblasts incorporated significantly less radiolabel compared with control cells. However, fractionation and analysis of the different classes of glycans indicated that the decrease in [3H]fucose incorporation is not generalized and is mainly confined to terminal fucosylation of N-linked oligosaccharides. In contrast, the total levels of protein O-fucosylation, including that observed in Notch protein, were unaffected. This finding demonstrates that the decrease in GDP-l-fucose levels in the fibroblast Golgi caused by the LAD II defect does not impair bulk protein O-fucosylation, but severely affects the bulk addition of fucose as a terminal modification of N-linked glycans. These data suggest that the severe clinical abnormalities including neurological and developmental ones observed in at least some of the LAD II patients may be related to alteration in recognition systems involving terminal fucose modifications of N-glycans and not be due to a defective O-fucosylation of proteins such as Notch.
Footnotes
-
↵1 The abbreviations used are: EGF, epidermal growth factor-like; LAD II/CGDS IIc, Leukocyte Adhesion Deficiency type II/Congenital Disorder of Glycosylation IIc; TSR, thrombospondin type 1 repeat; PNGase F, protein N-glycosidase F; HPAEC-PAD, high pH anion exchange chromatography-pulsed amperometric detection.
-
↵2 Y. Luo and R. S. Haltiwanger, unpublished data.
-
↵3 N. Taniguchi, personal communication (to R. S. H.).
-
↵* This work was supported by Grant GM61226 from the National Institutes of Health (to R. S. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Received April 17, 2003.
- Revision received May 2, 2003.
- The American Society for Biochemistry and Molecular Biology, Inc.











